How often do highly promising cancer biology discoveries translate into effective treatments?

Published:October 29, 2020DOI:
      The rate and speed with which cancer biology discoveries translate into clinical practice have importance for oncologists, researchers, and policy makers. A prior study found that among 101 science articles claiming a highly promising result for clinical translation, only 19 of 101 (18.8%) interventions had positive randomized trials, whereas five had been licensed for clinical use with a median follow-up of 12 years.
      • Contopoulos-Ioannidis D.G.
      • Ntzani E.
      • Ioannidis J.P.A.
      Translation of highly promising basic science research into clinical applications.
      To read this article in full you will need to make a payment
      Subscribe to Annals of Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Contopoulos-Ioannidis D.G.
        • Ntzani E.
        • Ioannidis J.P.A.
        Translation of highly promising basic science research into clinical applications.
        Am J Med. 2003; 114: 477-484
        • Joensuu H.
        Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
        Med Klin (Munich). 2002; 97: 28-30
        • Peifer C.
        • Alessi D.R.
        New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen.
        Biochem J. 2009; 417: e5-e7
        • Ebert A.D.
        • Ulrich U.
        • Beckmann M.W.
        • Schneider A.
        Zentralbl Gynakol. 2006; 128: 23-26
        • te Velde E.A.
        • Kusters B.
        • Maass C.
        • de Waal R.
        • Borel Rinkes I.H.M.
        Histological analysis of defective colonic healing as a result of angiostatin treatment.
        Exp Mol Pathol. 2003; 75: 119-123
      1. STD vaccine breakthrough. Cervarix would prevent human papilloma virus which can lead to cervical cancer; FDA approval anticipated.
        Health News Walth Mass. 2005; 11: 6-7
        • Semiglazov V.P.
        Vopr Onkol. 2001; 47: 195-199
        • Raben D.
        • Bianco C.
        • Helfrich B.
        • Weng E.
        • Ciardiello F.
        • Harari P.
        Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
        Expert Rev Anticancer Ther. 2002; 2: 461-471
        • Harari P.M.
        • Huang S.M.
        Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
        Semin Radiat Oncol. 2001; 11: 281-289
        • Scheithauer W.
        • Van Cutsem E.
        The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
        Colorectal Dis. 2003; 5: 36-44
        • Santiago-Schwarz F.
        Dendritic cells: friend or foe in autoimmunity?.
        Rheum Dis Clin North Am. 2004; 30: 115-134
        • Drew Y.
        • Calvert H.
        The potential of PARP inhibitors in genetic breast and ovarian cancers.
        Ann N Y Acad Sci. 2008; 1138: 136-145
        • Grégoire M.
        • Ebstein F.
        Bull Cancer (Paris). 2007; 94: 23-31
        • Irvine A.S.
        • Trinder P.K.
        • Laughton D.L.
        • et al.
        Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
        Nat Biotechnol. 2000; 18: 1273-1278
        • Walensky L.D.
        BCL-2 in the crosshairs: tipping the balance of life and death.
        Cell Death Differ. 2006; 13: 1339-1350
        • Liu X.-Y.
        • Qiu S.-B.
        • Zou W.-G.
        • et al.
        Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
        Mol Ther. 2005; 11: 531-541
        • Lund-Johansen F.
        • Olweus J.
        Tidsskr Den Nor Laegeforening. 1999; 119: 2510-2514
        • Lundstrom K.
        • Boulikas T.
        Viral and non-viral vectors in gene therapy: technology development and clinical trials.
        Technol Cancer Res Treat. 2003; 2: 471-486